Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter McLaughlin

Showing results (51-60 of 116) with videos related to

Pageof 12
Sort By:
Seminars in Oncology|February 14, 2002
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasoneAndreas H Sarris, Yunfang Jiang, Apostolia M Tsimberidou, et al.
Seminars in Oncology|February 1, 2017
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasoneAndreas H Sarris, Yunfang Jiang, Apostolia M Tsimberidou, et al.
Blood|March 3, 2005
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alphaPeter McLaughlin, Elihu Estey, Armand Glassman, et al.
British Journal of Haematology|December 20, 2015
Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicityChan Y Cheah, Loretta J Nastoupil, Peter McLaughlin, et al.
Leukemia & Lymphoma|October 26, 2011
Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up studyNicolas Batty, Fredrick B Hagemeister, Lei Feng, et al.
Cancer|June 11, 2005
Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimenApostolia-Maria Tsimberidou, Anas Younes, Jorge Romaguera, et al.
British Journal of Haematology|April 18, 2013
Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphomaYasuhiro Oki, Anas Younes, Amanda Copeland, et al.
Leukemia & Lymphoma|September 8, 2011
Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomasNina Shah, Fernando Cabanillas, Bradley McIntyre, et al.
Cancer|March 17, 2004
Thalidomide for patients with recurrent lymphomaBarbara Pro, Anas Younes, Maher Albitar, et al.
Leukemia & Lymphoma|September 14, 2020
Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphomaFelipe Samaniego, Peter McLaughlin, Sattva S Neelapu, et al.
Pageof 12

Showing results (51-60 of 116) with videos related to

Sort By:
Pageof 12
Seminars in Oncology|February 14, 2002
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasoneAndreas H Sarris, Yunfang Jiang, Apostolia M Tsimberidou, et al.
Seminars in Oncology|February 1, 2017
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasoneAndreas H Sarris, Yunfang Jiang, Apostolia M Tsimberidou, et al.
Blood|March 3, 2005
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alphaPeter McLaughlin, Elihu Estey, Armand Glassman, et al.
British Journal of Haematology|December 20, 2015
Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicityChan Y Cheah, Loretta J Nastoupil, Peter McLaughlin, et al.
Leukemia & Lymphoma|October 26, 2011
Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up studyNicolas Batty, Fredrick B Hagemeister, Lei Feng, et al.
Cancer|June 11, 2005
Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimenApostolia-Maria Tsimberidou, Anas Younes, Jorge Romaguera, et al.
British Journal of Haematology|April 18, 2013
Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphomaYasuhiro Oki, Anas Younes, Amanda Copeland, et al.
Leukemia & Lymphoma|September 8, 2011
Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomasNina Shah, Fernando Cabanillas, Bradley McIntyre, et al.
Cancer|March 17, 2004
Thalidomide for patients with recurrent lymphomaBarbara Pro, Anas Younes, Maher Albitar, et al.
Leukemia & Lymphoma|September 14, 2020
Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphomaFelipe Samaniego, Peter McLaughlin, Sattva S Neelapu, et al.
Pageof 12